Par

Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

Retrieved on: 
Martedì, Gennaio 4, 2022
Safety, Merz Pharma, Food, Endo International, Regulation of tobacco by the U.S. Food and Drug Administration, Bankruptcy, Merz, Par, Life, U.S. Securities and Exchange Commission, Phrase, Risk, Annual report, General manager, Private Securities Litigation Reform Act, Bromide, NASDAQ, LinkedIn, Senior, Compliance, LLC, Legislation, Industry, Public expenditure, Pharmaceutical industry, IQVIA

"We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo.

Key Points: 
  • "We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo.
  • "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic productsand our reputation for dependable quality is an especially essential factor when treating children."
  • According to IQVIA, CUVPOSA sales were approximately $27 million for the 12 months ended October 31, 2021.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.

Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

Retrieved on: 
Martedì, Gennaio 4, 2022
Safety, View, Merz Pharma, Food, Endo International, Regulation of tobacco by the U.S. Food and Drug Administration, Bankruptcy, Merz, Par, Life, U.S. Securities and Exchange Commission, Phrase, Risk, Annual report, General manager, Private Securities Litigation Reform Act, Bromide, NASDAQ, LinkedIn, Senior, Compliance, LLC, Legislation, Multimedia, Industry, Public expenditure, Pharmaceutical industry, IQVIA

"We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo.

Key Points: 
  • "We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo.
  • "Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic productsand our reputation for dependable quality is an especially essential factor when treating children."
  • According to IQVIA, CUVPOSA sales were approximately $27 million for the 12 months ended October 31, 2021.
  • Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

Retrieved on: 
Lunedì, Dicembre 20, 2021
Professional Services, Health, Legal, Clinical Trials, Pharmaceutical, Biotechnology, Medication, ANDA, CNS, FDA, Par, Douglas v. U.S. District Court ex rel Talk America, Failure, Compliance, Security (finance), Phrase, U.S. Securities and Exchange Commission, COVID-19, Drug development, Nasdaq, Research, Private Securities Litigation Reform Act, Forward-looking statement, Company, SEC, District court, European Medicines Agency, District, Pharmaceutical industry, Eagle

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Par Pharmaceutical, Inc. (Par) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagles recently approved vasopressin product.

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Par Pharmaceutical, Inc. (Par) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagles recently approved vasopressin product.
  • Pars appeal of the District Courts ruling on August 31, 2021, that Eagles vasopressin product does not infringe any of the patents asserted by Par against Eagle remains pending, and Eagle will continue to vigorously defend against such appeal.
  • We look forward to advancing our launch plans for this important product, and we believe this withdrawal re-affirms our confidence in ultimate success, stated Scott Tarriff, President and Chief Executive Officer of Eagle.
  • Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise.

Margaritaville Sets Sail with Margaritaville at Sea

Retrieved on: 
Mercoledì, Dicembre 8, 2021
PALM, Par, Water, Lake, Leisure, Food, CEO, Industry, Margaritaville, Partnership, Sand, Grand Classica, Bahamas Paradise Cruise Line, JWB, Instagram, Health, Facebook, Marghera, Port of Palm Beach, Hotel, Tourism

PALM BEACH, Fla., Dec. 8, 2021 /PRNewswire/ --Today, Margaritaville announces Margaritaville at Sea, an offshore resort experience.

Key Points: 
  • PALM BEACH, Fla., Dec. 8, 2021 /PRNewswire/ --Today, Margaritaville announces Margaritaville at Sea, an offshore resort experience.
  • "Margaritaville at Sea will be a new, exciting, and fun way for guests to escape and vacation in Margaritaville," said John Cohlan, CEO of Margaritaville.
  • "From oceans to lakes, Margaritaville has an organic tie to the water and with Margaritaville at Sea, we're able to put our iconic lifestyle, resort experiences, and elevated service directly on the sea.
  • She has opened many new markets and frontiers during her lifetime, so it is fitting that Margaritaville Paradise will again be a pioneer for Margaritaville at Sea.

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer

Retrieved on: 
Mercoledì, Dicembre 8, 2021
Science, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Genetics, Clinical Trials, Bone marrow failure, Endo, Lists of diseases, General counsel, Fanconi anemia, Business development, Heart failure, Endo International, SEC, Compliance, Biotechnology, Par, Human resources, Risk, Villanova University, Leadership, Genetic disorder, FA, Safety, Drug development, IMO, Private Securities Litigation Reform Act, PKD, Food, Patient, Danon disease, Corporation, LVV, Human, Pyruvate kinase deficiency, Lifting, Senior, COVID-19, Osteopetrosis, Medication, FDA, Marketing, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Law, AAV, Juris Doctor, License, Acquisition, Schering-Plough, Assistant, Management, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President.
  • Prior to joining Rocket, Mr. Wilson was General Counsel and Chief Corporate Officer at Ichnos Sciences, where he oversaw Legal, Compliance, Business Development, Human Resources and IT.
  • Before Ichnos, Mr. Wilson served as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources at Teligent, Inc.
  • Prior to Teligent, he was Vice President and Assistant General Counsel at Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals.

Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care

Retrieved on: 
Lunedì, Novembre 8, 2021
Legislation, Mission statement, Compliance, View, Premier, Industry, Private Securities Litigation Reform Act, Critical care, USP, General manager, U.S. Securities and Exchange Commission, NASDAQ, System, Risk, Senior, COVID-19, Multimedia, Research, Endo International, Natural borrowing limit, Public expenditure, LinkedIn, Par, Patient, Life, Pharmaceutical industry

"As a longstanding Premier partner, we welcome the opportunity to work with them via their Premier ProRx program to offer VASOSTRICTthrough their robust and highly reliable supply channel."

Key Points: 
  • "As a longstanding Premier partner, we welcome the opportunity to work with them via their Premier ProRx program to offer VASOSTRICTthrough their robust and highly reliable supply channel."
  • Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.
  • Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care

Retrieved on: 
Lunedì, Novembre 8, 2021
Legislation, Mission statement, Compliance, Premier, Industry, Private Securities Litigation Reform Act, Critical care, USP, General manager, U.S. Securities and Exchange Commission, NASDAQ, System, Risk, Senior, COVID-19, Research, Endo International, Natural borrowing limit, Public expenditure, LinkedIn, Par, Patient, Life, Pharmaceutical industry

"As a longstanding Premier partner, we welcome the opportunity to work with them via their Premier ProRx program to offer VASOSTRICTthrough their robust and highly reliable supply channel."

Key Points: 
  • "As a longstanding Premier partner, we welcome the opportunity to work with them via their Premier ProRx program to offer VASOSTRICTthrough their robust and highly reliable supply channel."
  • Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.
  • Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward.
  • Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Par Pacific Publishes Inaugural Sustainability Report

Retrieved on: 
Martedì, Novembre 2, 2021
Safety, Par Pacific Holdings, Workforce, NYSE, Achievement, Sustainability reporting, LLC, Par, Pacific Northwest, Sustainability, GLOBE, Natural gas, Risk management

HOUSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (ParPacific) today published its inaugural Sustainability Report.

Key Points: 
  • HOUSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (ParPacific) today published its inaugural Sustainability Report.
  • In his introduction to the report, Par Pacifics President and Chief Executive Officer, William Pate writes:
    I am proud to share our inaugural sustainability report with you.
  • The report details Par Pacifics sustainability mindset while also providing metrics on safety, greenhouse gas emissions, community engagement and its workforce, among other areas.
  • To access the Sustainability Report, please visit the Sustainability section of Par Pacifics website at https://www.parpacific.com/sustainability .

Gateway Casinos & Entertainment Limited Completes Refinancing of Corporate Debt in USD $1.25 Billion Transaction

Retrieved on: 
Lunedì, Ottobre 25, 2021
Professional Services, Entertainment, Other Professional Services, General Entertainment, Finance, Banking, Casino, Gaming, EBITDA, USD, Catalysis, US, Fortification, CAD, Casinos, LEEFF, Atlas, PIK, Communications and Entertainment Limited, Risk, Fortress Investment Group, SOFR, Senior, Food, Par, Pub, COVID-19, Philosophy, Program, COVID, Sale, Security (finance), Oil, Bank, Financial services, Gateway Casinos & Entertainment Limited, Fortress, The Catalyst Capital Group, GATEWAY CASINOS & ENTERTAINMENT LIMITED, FORTRESS, THE CATALYST CAPITAL GROUP

Gabriel de Alba, Executive Chairman of Gateway, said, We are very pleased to have completed this significant refinancing with Fortress as the lead investor.

Key Points: 
  • Gabriel de Alba, Executive Chairman of Gateway, said, We are very pleased to have completed this significant refinancing with Fortress as the lead investor.
  • Net proceeds from the transaction were used to refinance all of Gateways existing corporate debt at both Gateway Casinos & Entertainment Limited and GTWY Holdings Limited, including the Large Employer Emergency Financing Facility loan agreed to in September 2020, simplifying the Companys capital structure.
  • In connection with this refinancing transaction, Gateway received a meaningful corporate credit rating upgrade at Moodys to Caa1 (Positive Outlook).
  • Gateway Casinos & Entertainment Limited (Gateway) is one of the largest and most diversified gaming and entertainment companies in Canada with 26 gaming properties in British Columbia and Ontario and two additional properties in Edmonton, Alberta.

Par Pacific Announces Third Quarter 2021 Earnings Release and Conference Call Schedule

Retrieved on: 
Mercoledì, Ottobre 13, 2021
Pacific Northwest, Par Pacific Holdings, New, Par, NYSE, LLC, GLOBE, Natural gas, Investor, Central Time, Internet service provider

HOUSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (Par Pacific) today announced that it will release its third quarter 2021 results after the New York Stock Exchange closes on Wednesday, November 3, 2021.

Key Points: 
  • HOUSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (Par Pacific) today announced that it will release its third quarter 2021 results after the New York Stock Exchange closes on Wednesday, November 3, 2021.
  • This release will be followed by a conference call for investors on Thursday, November 4, 2021 at 9:00 a.m. Central Time (10:00 a.m. Eastern).
  • The full text of the release will be available on Par Pacifics website at http://www.parpacific.com .
  • Par Pacific also owns 46% of Laramie Energy, LLC, a natural gas production company with operations and assets concentrated in Western Colorado.